Funding for this research was provided by:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (K24-HD88229)
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases (T32 AI07140)
Division of Cancer Epidemiology and Genetics, National Cancer Institute (K08-CA228761)
Received: 11 May 2022
Accepted: 30 August 2022
First Online: 8 September 2022
: This research was approved by the Kenyatta National Hospital – University of Nairobi Ethics and Research Committee and the University of Washington Institutional Review Board (STUDY00001851).
: Not applicable.
: RSM received research funding, paid to the University of Washington from Hologic Corporation, and has received honoraria from consulting from Lupin Pharmaceuticals. RVB received abstract and manuscript writing support from Regeneron Pharmaceuticals, outside the submitted work.